Cancer is a well-known condition associated with its treatment and follow-up and increases the risk of thrombosis. As with solid tumors, the risk of venous thromboembolism (VTE) is quite high in lymphomas, especially high-grade B-cell lymphomas. Diffuse large B-cell lymphoma (DLBCL) patients are the most important part of this group. The aim of our study is to determine the effect of ferritin level at the time of diagnosis on thrombosis in DLBCL patients.

In this retrospective study, 133 patients who applied to SBU Dışkapı Yıldırım Beyazıt Training and Research Hospital Hematology clinic and were diagnosed with DLBCL were included in this retrospective study. Demographic characteristics, disease-related findings, presence of central venous catheter and laboratory results of the patients were recorded.

The median age of the patients included in the study was 63.13±14.85 years. There were 67 female and 66 male patients, stage 1-2: 54 patients, stage 3-4: 79 patients at the time of diagnosis. Thrombosis was observed in 16 of the patients. Median ferritin levels were 357.42 ug/L and 253.07 ug/L, respectively, between the group with and without thrombosis (p:0.026). The ferritin value, which was examined for the presence of thrombosis, was determined as 227 ug/L as a result of the ROC analysis. In the logistic regression analysis, the risk of developing thrombosis was 6.1 times higher in those with a ferritin level ≥227 ug/L.

Hyperferritinemia may be an independent risk factor for the development of thrombosis in DLBCL patients. In case of hyperferritinemia in patients, initiation of thromboprophylaxis may be an appropriate approach.